Menu Close

Hohimer Wealth Management LLC Raises Stock Position in Johnson & Johnson (NYSE:JNJ)

view original post

Hohimer Wealth Management LLC lifted its stake in shares of Johnson & Johnson (NYSE:JNJGet Rating) by 5.1% during the first quarter, HoldingsChannel.com reports. The fund owned 22,768 shares of the company’s stock after buying an additional 1,109 shares during the quarter. Hohimer Wealth Management LLC’s holdings in Johnson & Johnson were worth $4,035,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of JNJ. Riversedge Advisors LLC increased its holdings in Johnson & Johnson by 8.6% during the fourth quarter. Riversedge Advisors LLC now owns 3,664 shares of the company’s stock valued at $627,000 after buying an additional 289 shares during the period. Grove Bank & Trust boosted its stake in Johnson & Johnson by 1.6% in the fourth quarter. Grove Bank & Trust now owns 16,779 shares of the company’s stock valued at $2,871,000 after acquiring an additional 261 shares in the last quarter. LifePro Asset Management boosted its stake in Johnson & Johnson by 20.8% in the fourth quarter. LifePro Asset Management now owns 5,522 shares of the company’s stock valued at $945,000 after acquiring an additional 951 shares in the last quarter. Adviser Investments LLC boosted its stake in Johnson & Johnson by 4.0% in the fourth quarter. Adviser Investments LLC now owns 75,149 shares of the company’s stock valued at $12,856,000 after acquiring an additional 2,872 shares in the last quarter. Finally, Commonwealth Equity Services LLC lifted its stake in shares of Johnson & Johnson by 1.4% during the fourth quarter. Commonwealth Equity Services LLC now owns 1,736,541 shares of the company’s stock worth $297,070,000 after buying an additional 23,765 shares during the period. 68.78% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Johnson & Johnson

In other news, CAO Robert J. Decker sold 8,462 shares of the company’s stock in a transaction that occurred on Thursday, May 26th. The shares were sold at an average price of $180.00, for a total value of $1,523,160.00. Following the transaction, the chief accounting officer now directly owns 15,473 shares in the company, valued at approximately $2,785,140. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In related news, CAO Robert J. Decker sold 8,462 shares of the company’s stock in a transaction that occurred on Thursday, May 26th. The shares were sold at an average price of $180.00, for a total transaction of $1,523,160.00. Following the sale, the chief accounting officer now directly owns 15,473 shares of the company’s stock, valued at approximately $2,785,140. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Kathryn E. Wengel sold 40,000 shares of the company’s stock in a transaction that occurred on Friday, June 10th. The stock was sold at an average price of $173.00, for a total transaction of $6,920,000.00. Following the sale, the executive vice president now directly owns 71,311 shares in the company, valued at $12,336,803. The disclosure for this sale can be found here. Company insiders own 0.35% of the company’s stock.

Johnson & Johnson Stock Performance

NYSE:JNJ opened at $172.92 on Wednesday. The company has a debt-to-equity ratio of 0.39, a current ratio of 1.39 and a quick ratio of 1.14. The firm has a market capitalization of $455.02 billion, a price-to-earnings ratio of 25.17, a PEG ratio of 3.32 and a beta of 0.59. The company’s 50-day moving average is $175.67 and its two-hundred day moving average is $174.49. Johnson & Johnson has a 1-year low of $155.72 and a 1-year high of $186.69.

Johnson & Johnson (NYSE:JNJGet Rating) last posted its earnings results on Tuesday, July 19th. The company reported $2.59 earnings per share for the quarter, beating the consensus estimate of $2.57 by $0.02. Johnson & Johnson had a net margin of 19.21% and a return on equity of 36.56%. The company had revenue of $24.02 billion for the quarter, compared to analyst estimates of $23.85 billion. During the same period in the previous year, the business posted $2.48 EPS. Johnson & Johnson’s revenue was up 3.0% on a year-over-year basis. Analysts forecast that Johnson & Johnson will post 10.05 EPS for the current year.

Johnson & Johnson Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 6th. Stockholders of record on Tuesday, August 23rd will be issued a $1.13 dividend. The ex-dividend date of this dividend is Monday, August 22nd. This represents a $4.52 annualized dividend and a dividend yield of 2.61%. Johnson & Johnson’s dividend payout ratio is currently 65.79%.

Analysts Set New Price Targets

Several brokerages recently issued reports on JNJ. SVB Leerink reduced their target price on shares of Johnson & Johnson from $200.00 to $194.00 in a report on Wednesday, July 20th. Citigroup cut their price objective on shares of Johnson & Johnson from $205.00 to $201.00 in a report on Wednesday, July 20th. Credit Suisse Group lifted their price objective on shares of Johnson & Johnson from $200.00 to $205.00 and gave the company an “outperform” rating in a report on Wednesday, April 20th. The Goldman Sachs Group lifted their price objective on shares of Johnson & Johnson from $163.00 to $181.00 and gave the company a “neutral” rating in a report on Tuesday, April 12th. Finally, Raymond James boosted their target price on shares of Johnson & Johnson from $195.00 to $196.00 and gave the stock an “outperform” rating in a research note on Wednesday, April 20th. Four investment analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, Johnson & Johnson presently has an average rating of “Moderate Buy” and a consensus target price of $189.89.

Johnson & Johnson Company Profile

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company’s Consumer Health segment offers baby care products under the JOHNSON’S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

See Also

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Receive News & Ratings for Johnson & Johnson Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Johnson & Johnson and related companies with MarketBeat.com’s FREE daily email newsletter.